A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...

The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...

Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...

Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous polyposis, ...

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal ...

1 Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, Seattle, WA, United States 2 UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, WA, ...

Multi-target stool DNA test adherence among average-risk 45- to 49-year-old patients from 2017-2023. Refining colorectal cancer screening strategies using polygenic risk scores and classical risk ...

Total neoadjuvant therapy with FOLFOX plus bevacizumab and short-course radiotherapy for Ras mutant, high-risk, locally advanced rectal cancer: The TRAINER trial. Phase Ib study of gevokizumab (GEVO) ...